Michnowska M, Klin M J, Mroczka T, Mularczyk E, Lao M
Instytutu Transplantologii AM w Warszawie.
Pol Tyg Lek. 1993;48(50-52):867-9.
Eleven kidney transplant recipients with the oral or/and throat candidiasis which occurred during the first 3 months after transplantation were studied. Fluconazole was administered orally in the dose of 50 mg each 24, 48, 72 h, according to creatinine clearance. No clinical symptoms of candidiasis on the third day of the treatment were observed. In all patients, negative mucosal cultures were noted at the 8th day after first fluconazole dose. During fluconazole was with in normal range. Furthermore, no changes in serum bilirubin alanine transaminase, lactate dehydrogenase and alkaline phosphatase activities were observed. Serum creatinine decreased during this follow-up. In the 30th day after fluconazole administration cessation the mycological evidence of Candida p. reinfection were noted in 25% of patients. Fluconazole is highly efficient and safe agent to manage the oral and throat candidiasis in renal transplant recipients.
对11例在移植后前3个月发生口腔或/和咽喉念珠菌病的肾移植受者进行了研究。根据肌酐清除率，每24、48、72小时口服氟康唑50毫克。治疗第三天未观察到念珠菌病的临床症状。在所有患者中，首次服用氟康唑后第8天黏膜培养呈阴性。氟康唑治疗期间各项指标均在正常范围内。此外，血清胆红素、丙氨酸转氨酶、乳酸脱氢酶和碱性磷酸酶活性均未观察到变化。随访期间血清肌酐下降。在停用氟康唑后第30天，25%的患者出现念珠菌再感染的真菌学证据。氟康唑是治疗肾移植受者口腔和咽喉念珠菌病的高效安全药物。
